checkAd

     293  0 Kommentare RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules - Seite 3

    Investor and Media Relations for RVL Pharmaceuticals plc

    Lesen Sie auch

    Lisa M. Wilson
    In-Site Communications, Inc.
    T: 212-452-2793
    E: lwilson@insitecony.com



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules - Seite 3 BRIDGEWATER, N.J., Aug. 16, 2023 (GLOBE NEWSWIRE) - RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ (oxymetazoline hydrochloride ophthalmic solution), …